Mathieu F Chevalier

List of Publications by Year
in descending order

32 papers	1,428 citations	471509 17 h-index	477307 29 g-index
32 all docs	32 docs citations	32 times ranked	2624 citing authors

#	Article	IF	Citations
1	The split personality of regulatory T cells in HIV infection. Blood, 2013, 121, 29-37.	1.4	192
2	ILC2-modulated T cell–to-MDSC balance is associated with bladder cancer recurrence. Journal of Clinical Investigation, 2017, 127, 2916-2929.	8.2	176
3	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nature Communications, 2017, 8, 593.	12.8	175
4	HIV-1-Specific Interleukin-21 $^{+}$ CD4 $^{+}$ T Cell Responses Contribute to Durable Viral Control through the Modulation of HIV-Specific CD8 $^{+}$ T Cell Function. Journal of Virology, 2011, 85, 733-741.	3.4	173
5	The multifaceted immune regulation of bladder cancer. Nature Reviews Urology, 2019, 16, 613-630.	3.8	123
6	The Th17/Treg Ratio, IL-1RA and sCD14 Levels in Primary HIV Infection Predict the T-cell Activation Set Point in the Absence of Systemic Microbial Translocation. PLoS Pathogens, 2013, 9, e1003453.	4.7	91
7	Double Positive CD4+CD8+ T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization. Frontiers in Immunology, 2019, 10, 622.	4.8	55
8	Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy. European Urology, 2018, 74, 540-544.	1.9	53
9	Level of double negative T cells, which produce TGF-β and IL-10, predicts CD8 T-cell activation in primary HIV-1 infection. Aids, 2012, 26, 139-148.	2.2	52
10	Phenotype Alterations in Regulatory T-Cell Subsets in Primary HIV Infection and Identification of Tr1-like Cells as the Main Interleukin 10-Producing CD4+ T Cells. Journal of Infectious Diseases, 2015, 211, 769-779.	4.0	37
11	Epithelial adhesion molecules can inhibit HIV-1–specific CD8+ T-cell functions. Blood, 2011, 117, 5112-5122.	1.4	31
12	Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell–Mediated Tumor Regression in the MB49 Bladder Cancer Model. Cancer Immunology Research, 2019, 7, 621-629.	3.4	26
13	Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse. Blood, 2022, 140, 1305-1321.	1.4	23
14	Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer. European Urology, 2017, 71, 854-857.	1.9	22
15	γδ T-cell subsets in HIV controllers. Aids, 2019, 33, 1283-1292.	2.2	22
16	Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer. OncoImmunology, 2017, 6, e1265720.	4.6	19
17	The pro- and anti-tumor role of ILC2s. Seminars in Immunology, 2019, 41, 101276.	5.6	19
18	T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection. Aids, 2014, 28, 1683-1687.	2.2	18

#	Article	IF	Citations
19	High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. OncoImmunology, 2015, 4, e1029702.	4.6	17
20	CD4 T-Cell Responses in Primary HIV Infection: Interrelationship with Immune Activation and Virus Burden. Frontiers in Immunology, 2016, 7, 395.	4.8	17
21	Local *Salmonella* immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor. OncoImmunology, 2015, 4, e1016697.	4.6	11
22	Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy. , 2021, 9, e003123.		11
23	Real-world characteristics of T-cell apheresis and clinical response toÂtisagenlecleucel in B-cell lymphoma. Blood Advances, 2022, 6, 4657-4660.	5.2	11
24	Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 390-398.	2.1	10
25	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. Cancer Discovery, 2022, 12, 958-983.	9.4	10
26	Interleukin-1 receptor antagonist, a biomarker of response to anti-TB treatment in HIV/TB co-infected patients. Journal of Infection, 2017, 74, 456-465.	3.3	9
27	Immunotherapeutic strategies for bladder cancer. Human Vaccines and Immunotherapeutics, 2014, 10, 977-981.	3.3	6
28	Association of Plasma Soluble Vascular Cell Adhesion Molecule-1 and sCD14 With Mortality in HIV-1â€"Infected West African Adults With High CD4 Counts. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 138-145.	2.1	6
29	Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients. European Urology Focus, 2022, 8, 748-751.	3.1	6
30	Siglec-7 May Limit Natural Killer Cellâ€"mediated Antitumor responses in Bladder Cancer Patients. European Urology Open Science, 2021, 34, 79-82.	0.4	5
31	Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy. , 2021, 9, .		2
32	The early Th17/Treg ratio predicts the immune activation set point in patients with primary HIV infection. Retrovirology, 2012, 9, .	2.0	0